

Emergence of SARS-CoV-2 B.1.1.7 Lineage “ United States

Morbidity and Mortality Weekly Report

70, 95-99

DOI: [10.15585/mmwr.mm7003e2](https://doi.org/10.15585/mmwr.mm7003e2)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Impacts of Natural Environmental Factors and Prevalence of Airway Symptoms on the Local Spread of COVID-19: A Time-Series Analysis in Regional COVID-19 Epidemics. <i>Tohoku Journal of Experimental Medicine</i> , 2021, 254, 89-100.	0.5	2
2	A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351. <i>MAbs</i> , 2021, 13, 1930636.	2.6	13
3	Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines?. <i>Journal of Korean Medical Science</i> , 2021, 36, e124.	1.1	64
4	An overview of current COVID-19 vaccine platforms. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 2508-2517.	1.9	99
8	Molecular diagnostics in the era of COVID-19. <i>Analytical Methods</i> , 2021, 13, 3744-3763.	1.3	10
9	Newly designed analogues from SARS-CoV inhibitors mimicking the druggable properties against SARS-CoV-2 and its novel variants. <i>RSC Advances</i> , 2021, 11, 31460-31476.	1.7	1
10	CORONAVIRUSES – HOW PROTEIN INTERACTIONS CHANGED OUR PERCEPTION OF THE WORLD. <i>Postepy Mikrobiologii</i> , 2021, 60, 121-135.	0.1	0
11	A novel diagnostic test to screen SARS-CoV-2 variants containing E484K and N501Y mutations. <i>Emerging Microbes and Infections</i> , 2021, 10, 994-997.	3.0	15
12	Covid-19: Biden calls for science, vaccines, and masks. <i>BMJ, The</i> , 2021, 372, n150.	3.0	3
13	COVID-19 Surveillance of Healthcare Workers during the SARS-CoV-2 Vaccination Period: An Updated Protocol Suggestion. <i>Clinics</i> , 2021, 76, e3096.	0.6	1
14	Two Imported Cases of New Variant COVID-19 First Emerging from Brazil – Guangdong Province, China, April 30, 2021. <i>China CDC Weekly</i> , 2021, 3, 456-458.	1.0	3
16	Level of respiratory protection for healthcare workers caring for coronavirus disease 2019 (COVID-19) patients: A survey of hospital epidemiologists. <i>Infection Control and Hospital Epidemiology</i> , 2022, 43, 681-683.	1.0	2
22	Genome Sequence of a SARS-CoV-2 Strain from Bangladesh That Is Nearly Identical to United Kingdom SARS-CoV-2 Variant B.1.1.7. <i>Microbiology Resource Announcements</i> , 2021, 10, .	0.3	18
24	Importation of SARS-CoV-2 Variant B.1.1.7 in Pakistan. <i>Journal of Medical Virology</i> , 2021, 93, 2623-2625.	2.5	23
29	The challenge of emerging SARS-CoV-2 mutants to vaccine development. <i>Journal of Genetics and Genomics</i> , 2021, 48, 102-106.	1.7	19
35	Viral Vectors for COVID-19 Vaccine Development. <i>Viruses</i> , 2021, 13, 317.	1.5	65
36	First Identified Cases of SARS-CoV-2 Variant B.1.1.7 in Minnesota – December 2020–January 2021. <i>Morbidity and Mortality Weekly Report</i> , 2021, 70, 278-279.	9.0	24
51	Tracking SARS-CoV-2 lineage B.1.1.7 dissemination: insights from nationwide spike gene target failure (SGTF) and spike gene late detection (SGTL) data, Portugal, week 49 2020 to week 3 2021. <i>Eurosurveillance</i> , 2021, 26, .	3.9	64

#	ARTICLE	IF	CITATIONS
57	Mass religious gatherings events and COVID-19 – easing of COVID-19 restrictions and a staged approach to scaling up the Umrah Pilgrimage. <i>Travel Medicine and Infectious Disease</i> , 2021, 40, 101986.	1.5	9
58	Clinical and Economic Effects of Widespread Rapid Testing to Decrease SARS-CoV-2 Transmission. <i>Annals of Internal Medicine</i> , 2021, 174, 803-810.	2.0	43
59	SARS-CoV-2 Variants of Concern in the United States – Challenges and Opportunities. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1037.	3.8	288
60	Neutralizing Monoclonal Anti-SARS-CoV-2 Antibodies Isolated from Immunized Rabbits Define Novel Vulnerable Spike-Protein Epitope. <i>Viruses</i> , 2021, 13, 566.	1.5	23
63	Benchmarking SARS CoV-2 Infection in the Workplace to Support Continuity of Operations. <i>Journal of Occupational and Environmental Medicine</i> , 2021, 63, 548-556.	0.9	5
64	Consequences of coronavirus infections for primitive and mature hematopoietic cells: new insights and why it matters. <i>Current Opinion in Hematology</i> , 2021, 28, 231-242.	1.2	2
65	Impact of a New SARS-CoV-2 Variant on the Population: A Mathematical Modeling Approach. <i>Mathematical and Computational Applications</i> , 2021, 26, 25.	0.7	23
66	Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates – United States, March 1 – December 31, 2020. <i>Morbidity and Mortality Weekly Report</i> , 2021, 70, 350-354.	9.0	104
69	Travel from the United Kingdom to the United States by a Symptomatic Patient Infected with the SARS-CoV-2 B.1.1.7 Variant – Texas, January 2021. <i>Morbidity and Mortality Weekly Report</i> , 2021, 70, 348-349.	9.0	4
73	Coronavirus disease 2019 and pediatric anesthesia. <i>Current Opinion in Anaesthesiology</i> , 2021, 34, 292-298.	0.9	1
77	Analysis of the SARS-CoV-2-host protein interaction network reveals new biology and drug candidates: focus on the spike surface glycoprotein and RNA polymerase. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 1-15.	2.5	6
78	Simulated Identification of Silent COVID-19 Infections Among Children and Estimated Future Infection Rates With Vaccination. <i>JAMA Network Open</i> , 2021, 4, e217097.	2.8	22
81	A Perfect Storm? Health Anxiety, Contamination Fears, and COVID-19: Lessons Learned from Past Pandemics and Current Challenges. <i>International Journal of Cognitive Therapy</i> , 2021, 14, 497-513.	1.3	44
83	Metatranscriptomic Analysis Reveals SARS-CoV-2 Mutations in Wastewater of the Frankfurt Metropolitan Area in Southern Germany. <i>Microbiology Resource Announcements</i> , 2021, 10, .	0.3	23
84	Association of SARS-CoV-2 clades with clinical, inflammatory and virologic outcomes: An observational study. <i>EBioMedicine</i> , 2021, 66, 103319.	2.7	21
85	SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. <i>Cell Host and Microbe</i> , 2021, 29, 529-539.e3.	5.1	324
87	Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape. <i>ACS Nano</i> , 2021, 15, 5793-5818.	7.3	32
88	Inferring the Association between the Risk of COVID-19 Case Fatality and N501Y Substitution in SARS-CoV-2. <i>Viruses</i> , 2021, 13, 638.	1.5	21

#	ARTICLE	IF	CITATIONS
92	Analysis of Key Factors of a SARS-CoV-2 Vaccination Program: A Mathematical Modeling Approach. <i>Epidemiologia</i> , 2021, 2, 140-161.	1.1	22
93	Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. <i>Cell</i> , 2021, 184, 2372-2383.e9.	13.5	1,166
94	SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. <i>Cell</i> , 2021, 184, 2384-2393.e12.	13.5	848
97	Returning to a Normal Life via COVID-19 Vaccines in the United States: A Large-scale Agent-Based Simulation Study. <i>JMIR Medical Informatics</i> , 2021, 9, e27419.	1.3	55
99	Fundamental evolution of all <i>Orthocoronavirinae</i> including three deadly lineages descendent from Chiroptera-hosted coronaviruses: SARS-CoV, MERS-CoV and SARS-CoV-2. <i>Cladistics</i> , 2021, 37, 461-488.	1.5	16
102	SARS-CoV-2 variants: A double-edged sword?. <i>Experimental Biology and Medicine</i> , 2021, 246, 1721-1726.	1.1	19
103	Household water insecurity will complicate the ongoing COVID-19 response: Evidence from 29 sites in 23 low- and middle-income countries. <i>International Journal of Hygiene and Environmental Health</i> , 2021, 234, 113715.	2.1	41
105	Structural Analysis of the Novel Variants of SARS-CoV-2 and Forecasting in North America. <i>Viruses</i> , 2021, 13, 930.	1.5	13
106	Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. <i>Nature</i> , 2021, 594, 553-559.	13.7	199
107	Response to Comment on Gregory et al. COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemic's Impact in Type 1 and Type 2 Diabetes. <i>Diabetes Care</i> 2021;44:526-532. <i>Diabetes Care</i> , 2021, 44, e103-e104.	4.3	3
110	Reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.7 variant in an immunocompromised adolescent. <i>Infection Control and Hospital Epidemiology</i> , 2021, , 1-2.	1.0	6
112	Accelerated vaccine rollout is imperative to mitigate highly transmissible COVID-19 variants. <i>EClinicalMedicine</i> , 2021, 35, 100865.	3.2	100
113	Modeling of Future COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Rates and Nonpharmaceutical Intervention Scenarios – United States, April–September 2021. <i>Morbidity and Mortality Weekly Report</i> , 2021, 70, 719-724.	9.0	126
115	Differences in rapid increases in county-level COVID-19 incidence by implementation of statewide closures and mask mandates – United States, June 1–September 30, 2020. <i>Annals of Epidemiology</i> , 2021, 57, 46-53.	0.9	22
116	Effect of nasal suction catheter use on aerosol generation during endoscopic sinus surgery. <i>International Forum of Allergy and Rhinology</i> , 2021, 11, 1494-1496.	1.5	0
117	YouTube Videos and Informed Decision-Making About COVID-19 Vaccination: Successive Sampling Study. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e28352.	1.2	30
118	Review of Current COVID-19 Diagnostics and Opportunities for Further Development. <i>Frontiers in Medicine</i> , 2021, 8, 615099.	1.2	103
119	Early introductions and transmission of SARS-CoV-2 variant B.1.1.7 in the United States. <i>Cell</i> , 2021, 184, 2595-2604.e13.	13.5	113

#	ARTICLE	IF	CITATIONS
120	Mutations in the B.1.1.7 SARS-CoV-2 Spike Protein Reduce Receptor-Binding Affinity and Induce a Flexible Link to the Fusion Peptide. <i>Biomedicines</i> , 2021, 9, 525.	1.4	28
121	RT-qPCR Assays for Rapid Detection of the N501Y, 69-70del, K417N, and E484K SARS-CoV-2 Mutations: A Screening Strategy to Identify Variants With Clinical Impact. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 672562.	1.8	60
122	Tapping the immunological imprints to design chimeric SARS-CoV-2 vaccine for elderly population. <i>International Reviews of Immunology</i> , 2021, , 1-16.	1.5	6
123	The Emerging Concern and Interest SARS-CoV-2 Variants. <i>Pathogens</i> , 2021, 10, 633.	1.2	86
124	Epitope profiling reveals binding signatures of SARS-CoV-2 immune response in natural infection and cross-reactivity with endemic human CoVs. <i>Cell Reports</i> , 2021, 35, 109164.	2.9	44
125	siRNA Therapeutics for the Therapy of COVID-19 and Other Coronaviruses. <i>Molecular Pharmaceutics</i> , 2021, 18, 2105-2121.	2.3	34
126	Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike mutation T478K. <i>Journal of Medical Virology</i> , 2021, 93, 5638-5643.	2.5	129
127	SARS-CoV-2 B.1.1.7 variant of concern detected in a pet dog and cat after exposure to a person with COVID-19, USA. <i>Transboundary and Emerging Diseases</i> , 2022, 69, 1656-1658.	1.3	53
128	Factors Associated With Access to and Timing of Coronavirus Testing Among US Adults After Onset of Febrile Illness. <i>JAMA Network Open</i> , 2021, 4, e218500.	2.8	9
130	COVID-19 in normal, diseased and transplanted liver. <i>World Journal of Gastroenterology</i> , 2021, 27, 2576-2585.	1.4	5
131	Multiplex qPCR discriminates variants of concern to enhance global surveillance of SARS-CoV-2. <i>PLoS Biology</i> , 2021, 19, e3001236.	2.6	200
132	A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 213.	7.1	76
133	Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States. <i>Cell</i> , 2021, 184, 2587-2594.e7.	13.5	285
137	Intrafamilial Spread and Altered Symptomatology of SARS-CoV-2, During Predominant Circulation of Lineage B.1.1.7 Variant in Israel. <i>Pediatric Infectious Disease Journal</i> , 2021, 40, e310-e311.	1.1	10
138	Response to mutation and variants of the SARS-CoV-2 gene. <i>Universa Medicina</i> , 2021, 40, 77-78.	0.1	3
139	Volcanic Ash as a Precursor for SARS-CoV-2 Infection Among Susceptible Populations in Ecuador: A Satellite Imaging and Excess Mortality-Based Analysis. <i>Disaster Medicine and Public Health Preparedness</i> , 2021, , 1-13.	0.7	7
142	Authors' Reply. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 778-779.	1.2	0
144	The Emergence of SARS-CoV-2 Variant(s) and Its Impact on the Prevalence of COVID-19 Cases in the Nabatieh Region, Lebanon. <i>Medical Sciences (Basel, Switzerland)</i> , 2021, 9, 40.	1.3	14

#	ARTICLE	IF	CITATIONS
145	COVID-19 Pandemic in India: Through the Lens of Modeling. <i>Global Health, Science and Practice</i> , 2021, 9, 220-228.	0.6	12
146	Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis. <i>Molecules and Cells</i> , 2021, 44, 392-400.	1.0	22
147	COVID-19 pathophysiology and pharmacology: what do we know and how did Canadians respond? A review of Health Canada authorized clinical vaccine and drug trials. <i>Canadian Journal of Physiology and Pharmacology</i> , 2021, 99, 577-588.	0.7	2
148	Inefficient Placental Virus Replication and Absence of Neonatal Cell-Specific Immunity Upon Sars-CoV-2 Infection During Pregnancy. <i>Frontiers in Immunology</i> , 2021, 12, 698578.	2.2	22
149	Present variants of concern and variants of interest of severe acute respiratory syndrome coronavirus 2: Their significant mutations in Sâ€glycoprotein, infectivity, reâ€infectivity, immune escape and vaccines activity. <i>Reviews in Medical Virology</i> , 2022, 32, e2270.	3.9	71
150	Sequence Analysis of 20,453 Severe Acute Respiratory Syndrome Coronavirus 2 Genomes from the Houston Metropolitan Area Identifies the Emergence and Widespread Distribution of Multiple Isolates of All Major Variants of Concern. <i>American Journal of Pathology</i> , 2021, 191, 983-992.	1.9	42
151	Current Update on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development with a Special Emphasis on Gene Therapy Viral Vector Design and Construction for Vaccination. <i>Human Gene Therapy</i> , 2021, 32, 541-562.	1.4	9
152	SARS coronavirus outbreaks past and presentâ€a comparative analysis of SARS-CoV-2 and its predecessors. <i>Virus Genes</i> , 2021, 57, 307-317.	0.7	14
153	Dental care during COVIDâ€19 pandemic: Followâ€up survey of experts' opinion. <i>Clinical Oral Implants Research</i> , 2021, 32, 342-352.	1.9	8
154	Severe Acute Respiratory Syndrome Coronavirus 2: The Emergence of Important Genetic Variants and Testing Options for Clinical Laboratories. <i>Clinical Microbiology Newsletter</i> , 2021, 43, 89-96.	0.4	5
156	SARS-CoV-2 mutational variants may represent a new challenge to society, but not to the virucidal armamentarium. <i>Journal of Hospital Infection</i> , 2021, 112, 121-123.	1.4	4
157	Review of COVID-19 Variants and COVID-19 Vaccine Efficacy: What the Clinician Should Know?. <i>Journal of Clinical Medicine Research</i> , 2021, 13, 317-325.	0.6	134
158	Rapid Detection of SARS-CoV-2 Variants of Concern, Including B.1.1.28/P.1, British Columbia, Canada. <i>Emerging Infectious Diseases</i> , 2021, 27, 1673-1676.	2.0	38
159	Notable and Emerging Variants of SARS-CoV-2 Virus: A Quick Glance. <i>Indian Journal of Clinical Biochemistry</i> , 2021, 36, 451-458.	0.9	9
160	An Overview of the Epidemiologic, Diagnostic and Treatment Approaches of COVID-19: What do We Know?. <i>Public Health Reviews</i> , 2021, 42, 1604061.	1.3	6
162	SARS-CoV-2 Brazil variants in Latin America: More serious research urgently needed on public health and vaccine protection. <i>Annals of Medicine and Surgery</i> , 2021, 66, 102428.	0.5	18
163	Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity. <i>Science</i> , 2021, 373, .	6.0	318
164	COVID-19 Case Investigation and Contact Tracing in the US, 2020. <i>JAMA Network Open</i> , 2021, 4, e2115850.	2.8	68

#	ARTICLE	IF	CITATIONS
166	A Novel SARS-CoV-2 Viral Sequence Bioinformatic Pipeline Has Found Genetic Evidence That the Viral 3' UTR Is Evolving and Generating Increased Viral Diversity. <i>Frontiers in Microbiology</i> , 2021, 12, 665041.	1.5	20
167	Rapid screening for SARS-CoV-2 variants of concern in clinical and environmental samples using nested RT-PCR assays targeting key mutations of the spike protein. <i>Water Research</i> , 2021, 197, 117104.	5.3	92
170	COVID-19 pandemic: SARS-CoV-2 specific vaccines and challenges, protection via BCG trained immunity, and clinical trials. <i>Expert Review of Vaccines</i> , 2021, 20, 857-880.	2.0	32
172	The landscape of antibody binding in SARS-CoV-2 infection. <i>PLoS Biology</i> , 2021, 19, e3001265.	2.6	58
173	Multisystem Inflammatory Syndrome in Children and COVID-19 Infections. <i>NASN School Nurse (Print)</i> , 2021, 36, 1942602X2110211.	0.4	0
174	Genomic Surveillance for SARS-CoV-2 Variants Circulating in the United States, December 2020–May 2021. <i>Morbidity and Mortality Weekly Report</i> , 2021, 70, 846-850.	9.0	71
175	Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality. <i>ELife</i> , 2021, 10, .	2.8	38
178	COVID-19 and SARS-CoV-2 Variants: Current Challenges and Health Concern. <i>Frontiers in Genetics</i> , 2021, 12, 693916.	1.1	55
180	Specific allelic discrimination of N501Y and other SARS-CoV-2 mutations by ddPCR detects B.1.1.7 lineage in Washington State. <i>Journal of Medical Virology</i> , 2021, 93, 5931-5941.	2.5	31
181	SARS-CoV-2 B.1.617 Indian variants: Are electrostatic potential changes responsible for a higher transmission rate?. <i>Journal of Medical Virology</i> , 2021, 93, 6551-6556.	2.5	79
182	The UK Leicester COVID-19 "exceedance"™ May–July 2020: An analysis of hospitalised cases. <i>Journal of Infection</i> , 2021, 83, e5-e7.	1.7	1
183	Nonlinear Dynamics of the Introduction of a New SARS-CoV-2 Variant with Different Infectiousness. <i>Mathematics</i> , 2021, 9, 1564.	1.1	5
184	Antibodies Targeting Two Epitopes in SARS-CoV-2 Neutralize Pseudoviruses with the Spike Proteins from Different Variants. <i>Pathogens</i> , 2021, 10, 869.	1.2	2
185	SARS-CoV-2 variant evolution in the United States: High accumulation of viral mutations over time likely through serial Founder Events and mutational bursts. <i>PLoS ONE</i> , 2021, 16, e0255169.	1.1	28
186	Projecting the Impact of SARS-CoV-2 Variants and the Vaccination Program on the Fourth Wave of the COVID-19 Pandemic in South Korea. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7578.	1.2	27
187	Qualitative analysis of a mathematical model with presymptomatic individuals and two SARS-CoV-2 variants. <i>Computational and Applied Mathematics</i> , 2021, 40, 1.	1.0	14
188	mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. <i>Nature Medicine</i> , 2021, 27, 1614-1621.	15.2	337
190	Comparison and Sensitivity Evaluation of Three Different Commercial Real-Time Quantitative PCR Kits for SARS-CoV-2 Detection. <i>Viruses</i> , 2021, 13, 1321.	1.5	31

#	ARTICLE	IF	CITATIONS
191	COVID-19 Vaccines and Thrombosisâ€”Roadblock or Dead-End Street?. <i>Biomolecules</i> , 2021, 11, 1020.	1.8	28
192	Clinical performance evaluation of SARS-CoV-2 rapid antigen testing in point of care usage in comparison to RT-qPCR. <i>EBioMedicine</i> , 2021, 69, 103455.	2.7	63
193	Multiplex SARS-CoV-2 Genotyping Reverse Transcriptase PCR for Population-Level Variant Screening and Epidemiologic Surveillance. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0085921.	1.8	82
194	Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, India, and other COVID-19-devastated countries. <i>Genomics</i> , 2021, 113, 2158-2170.	1.3	164
196	Limitation of Screening of Different Variants of SARS-CoV-2 by RT-PCR. <i>Diagnostics</i> , 2021, 11, 1241.	1.3	16
197	Implications of inadequate water and sanitation infrastructure for community spread of COVID-19 in remote Alaskan communities. <i>Science of the Total Environment</i> , 2021, 776, 145842.	3.9	21
198	HIV infection and risk of COVID-19 mortality. <i>Medicine (United States)</i> , 2021, 100, e26573.	0.4	33
200	Comparative analysis of SARS-CoV-2 envelope viroporin mutations from COVID-19 deceased and surviving patients revealed implications on its ion-channel activities and correlation with patient mortality. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 10454-10469.	2.0	11
202	Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis. <i>JAMA Internal Medicine</i> , 2021, 181, 1306.	2.6	63
204	Emergence and Spread of B.1.1.7 Lineage in Primary Care and Clinical Impact in the Morbi-Mortality among Hospitalized Patients in Madrid, Spain. <i>Microorganisms</i> , 2021, 9, 1517.	1.6	12
205	Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease. <i>Cell Host and Microbe</i> , 2021, 29, 1151-1161.e5.	5.1	36
206	Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and function. <i>Nature Structural and Molecular Biology</i> , 2021, 28, 731-739.	3.6	124
207	American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease. <i>Hepatology</i> , 2021, 74, 1049-1064.	3.6	136
210	The potential use of <i>Drosophila</i> as an in vivo model organism for COVID-19-related research: a review. <i>Turkish Journal of Biology</i> , 2021, 45, 559-569.	2.1	4
211	Single-Amplicon Multiplex Real-Time Reverse Transcription-PCR with Tiled Probes To Detect SARS-CoV-2 <i>spike</i> Mutations Associated with Variants of Concern. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0144621.	1.8	26
212	SARS-CoV-2 Genome Sequencing Methods Differ in Their Abilities To Detect Variants from Low-Viral-Load Samples. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0104621.	1.8	33
213	Replicative Fitness of a SARS-CoV-2 20I/501Y.V1 Variant from Lineage B.1.1.7 in Human Reconstituted Bronchial Epithelium. <i>MBio</i> , 2021, 12, e0085021.	1.8	27
214	Efficient Inhibition of SARS-CoV-2 Using Chimeric Antisense Oligonucleotides through RNase L Activation**. <i>Angewandte Chemie</i> , 2021, 133, 21830-21835.	1.6	3

#	ARTICLE	IF	CITATIONS
215	Efficient Inhibition of SARS-CoV-2 Using Chimeric Antisense Oligonucleotides through RNase L Activation**. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 21662-21667.	7.2	21
218	Applications of laboratory findings in the prevention, diagnosis, treatment, and monitoring of COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 316.	7.1	17
219	Circulating SARS-CoV-2 variants in Italy, October 2020–March 2021. <i>Virology Journal</i> , 2021, 18, 168.	1.4	36
220	Cluster characterization of SARS-CoV-2 in military personnel deployed to Egypt and subsequent introduction of B.1.1.7 and C.36 lineages to Colombia. <i>Journal of Travel Medicine</i> , 2021, 28, .	1.4	1
221	Suspected Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) Reinfections: Incidence, Predictors, and Healthcare Use Among Patients at 238 US Healthcare Facilities, 1 June 2020 to 28 February 2021. <i>Clinical Infectious Diseases</i> , 2022, 74, 1489-1492.	2.9	24
222	Influenza Virus-like Particle (VLP) Vaccines Expressing the SARS-CoV-2 S Glycoprotein, S1, or S2 Domains. <i>Vaccines</i> , 2021, 9, 920.	2.1	16
223	A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 1652-1661.	5.7	24
224	Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial. <i>Infectious Diseases and Therapy</i> , 2021, 10, 2489-2509.	1.8	52
225	Alpha variant (B.1.1.7) of SARS-CoV-2 increases fatality-rate for patients under age of 70 years and hospitalization risk overall. <i>Acta Microbiologica Et Immunologica Hungarica</i> , 2021, , .	0.4	10
226	Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment. <i>MSphere</i> , 2021, 6, e0048021.	1.3	70
227	Effectiveness of Natural Antioxidants against SARS-CoV-2? Insights from the In-Silico World. <i>Antibiotics</i> , 2021, 10, 1011.	1.5	41
228	Improving Pandemic Response: Employing Mathematical Modeling to Confront Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2022, 74, 913-917.	2.9	36
229	Partial protection of Sinopharm vaccine against SARS COV2 during recent outbreak in Bahrain. <i>Microbial Pathogenesis</i> , 2021, 158, 105086.	1.3	15
230	Lectin from <i>Triticum vulgare</i> (WGA) Inhibits Infection with SARS-CoV-2 and Its Variants of Concern Alpha and Beta. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10205.	1.8	17
231	Epitope Profiling Reveals the Critical Antigenic Determinants in SARS-CoV-2 RBD-Based Antigen. <i>Frontiers in Immunology</i> , 2021, 12, 707977.	2.2	21
232	OmniSARS2: A Highly Sensitive and Specific RT-qPCR-Based COVID-19 Diagnostic Method Designed to Withstand SARS-CoV-2 Lineage Evolution. <i>Biomedicines</i> , 2021, 9, 1314.	1.4	8
233	Wastewater surveillance of SARS-CoV-2 across 40 U.S. states from February to June 2020. <i>Water Research</i> , 2021, 202, 117400.	5.3	119
235	A Comprehensive Overview on COVID-19: Future Perspectives. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 744903.	1.8	27

#	ARTICLE	IF	CITATIONS
236	Cerebral Vein Thrombosis With Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>Stroke</i> , 2021, 52, 3045-3053.	1.0	38
237	Could live attenuated vaccines better control COVID-19?. <i>Vaccine</i> , 2021, 39, 5719-5726.	1.7	29
238	Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. <i>Nature Microbiology</i> , 2021, 6, 1233-1244.	5.9	237
239	Mathematical Modeling of Vaccines That Prevent SARS-CoV-2 Transmission. <i>Viruses</i> , 2021, 13, 1921.	1.5	10
240	Exploring the Interaction between E484K and N501Y Substitutions of SARS-CoV-2 in Shaping the Transmission Advantage of COVID-19 in Brazil: A Modeling Study. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 105, 1247-1254.	0.6	5
241	The Impact of Vaccination Worldwide on SARS-CoV-2 Infection: A Review on Vaccine Mechanisms, Results of Clinical Trials, Vaccinal Coverage and Interactions with Novel Variants. <i>Current Medicinal Chemistry</i> , 2022, 29, 2673-2690.	1.2	12
242	Development and Efficacy of Lateral Flow Point-of-Care Testing Devices for Rapid and Mass COVID-19 Diagnosis by the Detections of SARS-CoV-2 Antigen and Anti-SARS-CoV-2 Antibodies. <i>Diagnostics</i> , 2021, 11, 1760.	1.3	28
245	Emergence of an early SARS-CoV-2 epidemic in the United States. <i>Cell</i> , 2021, 184, 4939-4952.e15.	13.5	31
247	A Simple Reverse Transcriptase PCR Melting-Temperature Assay To Rapidly Screen for Widely Circulating SARS-CoV-2 Variants. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0084521.	1.8	48
249	COVID-19 and Cancer Therapy: Interrelationships and Management of Cancer Cases in the Era of COVID-19. <i>Journal of Chemistry</i> , 2021, 2021, 1-10.	0.9	1
250	Model-driven mitigation measures for reopening schools during the COVID-19 pandemic. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	37
251	Performance Evaluation of the MatMaCorp COVID-19 2SF Assay for the Detection of SARS-CoV-2 from Nasopharyngeal Swabs. <i>Microbiology Spectrum</i> , 2021, 9, e0008321.	1.2	2
253	COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 690621.	1.8	60
255	Characteristics of SARS-CoV-2 Infections in Israeli Children During the Circulation of Different SARS-CoV-2 Variants. <i>JAMA Network Open</i> , 2021, 4, e2124343.	2.8	19
257	Human genetic basis of coronavirus disease 2019. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 344.	7.1	24
258	A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency. <i>Antiviral Research</i> , 2021, 194, 105147.	1.9	11
259	The use of face masks during vaccine roll-out in New YorkCity and impact on epidemic control. <i>Vaccine</i> , 2021, 39, 6296-6301.	1.7	10
260	COVID-19 antibody donation using immunoadsorption: Report of two cases. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103193.	0.5	4

#	ARTICLE	IF	CITATIONS
261	Trajectory of Growth of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in Houston, Texas, January through May 2021, Based on 12,476 Genome Sequences. <i>American Journal of Pathology</i> , 2021, 191, 1754-1773.	1.9	26
262	Evaluation of two RT-PCR screening assays for identifying SARS-CoV-2 variants. <i>Journal of Clinical Virology</i> , 2021, 143, 104969.	1.6	30
263	Patient Safety and Ethical Implications of Health Care Sick Leave Policies in the Pandemic Era. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2021, 47, 673-676.	0.4	1
264	Feasibility of neighborhood and building scale wastewater-based genomic epidemiology for pathogen surveillance. <i>Science of the Total Environment</i> , 2021, 789, 147829.	3.9	55
265	Deamidation drives molecular aging of the SARS-CoV-2 spike protein receptor-binding motif. <i>Journal of Biological Chemistry</i> , 2021, 297, 101175.	1.6	3
266	Is It Ethical to Mandate SARS-CoV-2 Vaccinations among Incarcerated Persons?. <i>American Journal of Bioethics</i> , 2022, 22, 8-10.	0.5	2
267	Effects of N95 Mask Use on Pulmonary Function in Children. <i>Journal of Pediatrics</i> , 2021, 237, 143-147.	0.9	20
268	SARS-CoV-2 new variants: Characteristic features and impact on the efficacy of different vaccines. <i>Biomedicine and Pharmacotherapy</i> , 2021, 143, 112176.	2.5	51
269	E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies. <i>Journal of Molecular Graphics and Modelling</i> , 2021, 109, 108035.	1.3	52
270	Phylogeneticity of B.1.1.7 surface glycoprotein, novel distance function and first report of V90T missense mutation in SARS-CoV-2 surface glycoprotein. <i>Meta Gene</i> , 2021, 30, 100967.	0.3	4
271	COVID-19 wastewater surveillance in rural communities: Comparison of lagoon and pumping station samples. <i>Science of the Total Environment</i> , 2021, 801, 149618.	3.9	36
272	Diagnostic pre-screening method based on N-gene dropout or delay to increase feasibility of SARS-CoV-2 VOC B.1.1.7 detection. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 101, 115491.	0.8	16
275	Second wave of COVID-19: Unrelenting rampage of the SARS CoV-2 variants. <i>Current Medical Issues</i> , 2021, 19, 129.	0.1	3
276	The emerging SARS-CoV-2 variants of concern. <i>Therapeutic Advances in Infectious Disease</i> , 2021, 8, 204993612110243.	1.1	82
277	A Next-Generation Vaccine Candidate Using Alternative Epitopes to Protect against Wuhan and All Significant Mutant Variants of SARS-CoV-2: An Immunoinformatics Approach. , 2021, 12, 2173.		20
278	Rapid Increase in SARS-CoV-2 P.1 Lineage Leading to Codominance with B.1.1.7 Lineage, British Columbia, Canada, January–April 2021. <i>Emerging Infectious Diseases</i> , 2021, 27, 2802-2809.	2.0	26
280	Enfermedad por coronavirus 2019 (COVID-19). <i>Medicina UPB</i> , 2021, 40, 41-49.	0.1	0
281	SARS-CoV-2: Pathogenic Mechanisms and Host Immune Response. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1313, 99-134.	0.8	6

#	ARTICLE	IF	CITATIONS
282	Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections. <i>Clinical and Translational Immunology</i> , 2021, 10, e1345.	1.7	14
284	Characteristics of SARS-CoV-2 positive individuals in California from two periods during notable decline in incident infection. <i>Health Science Reports</i> , 2021, 4, e384.	0.6	0
285	The evaluation of potential global impact of the N501Y mutation in SARS-CoV-2 positive patients. <i>Journal of Medical Virology</i> , 2022, 94, 1009-1019.	2.5	12
286	Long Term Immune Response Produced by the SputnikV Vaccine. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11211.	1.8	9
287	Molecular Analysis and Genome Sequencing of SARS-Cov-2 during Second Wave 2021 Revealed Variant Diversity in India. <i>Journal of Pure and Applied Microbiology</i> , 0, , .	0.3	1
288	Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments. <i>Current Molecular Medicine</i> , 2022, 22, 621-639.	0.6	2
289	Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy. <i>Vaccines</i> , 2021, 9, 1195.	2.1	90
290	Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 720357.	1.8	7
291	2021 Interim Guidance to Health Care Providers for Basic and Advanced Cardiac Life Support in Adults, Children, and Neonates With Suspected or Confirmed COVID-19. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e008396.	0.9	21
294	Development of a highly specific and sensitive VHH-based sandwich immunoassay for the detection of the SARS-CoV-2 nucleoprotein. <i>Journal of Biological Chemistry</i> , 2022, 298, 101290.	1.6	16
295	From Alpha to Zeta: Identifying Variants and Subtypes of SARS-CoV-2 Via Clustering. <i>Journal of Computational Biology</i> , 2021, 28, 1113-1129.	0.8	14
296	Evaluation of the clinical and analytical performance of the Seegene allplex [®] SARS-CoV-2 variants I assay for the detection of variants of concern (VOC) and variants of interests (VOI). <i>Journal of Clinical Virology</i> , 2021, 144, 104996.	1.6	16
297	Understanding mutation hotspots for the SARS-CoV-2 spike protein using Shannon Entropy and K-means clustering. <i>Computers in Biology and Medicine</i> , 2021, 138, 104915.	3.9	31
298	The first newborn patient with SARS-CoV-2 variant B.1.1.7 identified in Viet Nam: treatment and care practices. <i>Western Pacific Surveillance and Response Journal: WPSAR</i> , 2021, 12, 77-81.	0.3	2
299	mRNA-Based Vaccine BNT162b2 Might Reduce Severe Acute Respiratory Syndrome Coronavirus 2 B.1.1.7 Variant Transmission in Japanese Population. <i>Cureus</i> , 2021, 13, e19140.	0.2	0
300	Robust Virus-Specific Adaptive Immunity in COVID-19 Patients with SARS-CoV-2 Î”382 Variant Infection. <i>Journal of Clinical Immunology</i> , 2022, 42, 214-229.	2.0	15
301	A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge. <i>Npj Vaccines</i> , 2021, 6, 129.	2.9	47
302	Viral vector-based vaccines against SARS-CoV-2. <i>Exploration of Immunology</i> , 2021, , 295-308.	1.7	4

#	ARTICLE	IF	CITATIONS
303	Long-term surveillance of wastewater SARS-CoV-2 in Los Angeles County. <i>Environmental Science: Water Research and Technology</i> , 2021, 7, 2282-2294.	1.2	7
304	The Evolutionary Landscape of SARS-CoV-2 Variant B.1.1.519 and Its Clinical Impact in Mexico City. <i>Viruses</i> , 2021, 13, 2182.	1.5	31
305	Structural and functional insights into the spike protein mutations of emerging SARS-CoV-2 variants. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 7967-7989.	2.4	40
306	Performance Evaluation of Lateral Flow Assays for Coronavirus Disease-19 Serology. <i>Clinics in Laboratory Medicine</i> , 2022, 42, 31-56.	0.7	8
307	Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape. <i>Frontiers in Immunology</i> , 2021, 12, 744242.	2.2	44
308	Exposing structural variations in SARS-CoV-2 evolution. <i>Scientific Reports</i> , 2021, 11, 22042.	1.6	6
309	Receptor-Binding Domain Proteins of SARS-CoV-2 Variants Elicited Robust Antibody Responses Cross-Reacting with Wild-Type and Mutant Viruses in Mice. <i>Vaccines</i> , 2021, 9, 1383.	2.1	4
310	Sequencing Using a Two-Step Strategy Reveals High Genetic Diversity in the S Gene of SARS-CoV-2 after a High-Transmission Period in Tunis, Tunisia. <i>Microbiology Spectrum</i> , 2021, 9, e0063921.	1.2	7
311	Jeopardy of COVID-19: Rechecking the Perks of Phytotherapeutic Interventions. <i>Molecules</i> , 2021, 26, 6783.	1.7	4
312	National responses to covid-19: drivers, complexities, and uncertainties in the first year of the pandemic. <i>BMJ, The</i> , 2021, 375, e068954.	3.0	11
314	The N501Y spike substitution enhances SARS-CoV-2 infection and transmission. <i>Nature</i> , 2022, 602, 294-299.	13.7	364
315	Universally Stable and Precise CRISPR-LAMP Detection Platform for Precise Multiple Respiratory Tract Virus Diagnosis Including Mutant SARS-CoV-2 Spike N501Y. <i>Analytical Chemistry</i> , 2021, 93, 16184-16193.	3.2	36
316	The Dominance of Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617 and Its Sublineages and Associations with Mortality during the COVID-19 Pandemic in India between 2020 and 2021. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, 106, 142-149.	0.6	12
317	Cross-validation of SARS-CoV-2 responses in kidney organoids and clinical populations. <i>JCI Insight</i> , 2021, 6, .	2.3	21
318	Robust Representation and Efficient Feature Selection Allows for Effective Clustering of SARS-CoV-2 Variants. <i>Algorithms</i> , 2021, 14, 348.	1.2	16
319	Public Health Measures During the COVID-19 Pandemic Reduce the Spread of Other Respiratory Infectious Diseases. <i>Frontiers in Public Health</i> , 2021, 9, 771638.	1.3	17
320	B.1.1.7 Variant Outbreak in an Air Force Military Base—Real-World Data. <i>Military Medicine</i> , 2021, , .	0.4	0
321	Bayesian inference across multiple models suggests a strong increase in lethality of COVID-19 in late 2020 in the UK. <i>PLoS ONE</i> , 2021, 16, e0258968.	1.1	3

#	ARTICLE	IF	CITATIONS
322	Perspectives into the possible effects of the B.1.1.7 variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on spermatogenesis. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2021, .	0.7	0
323	Emerging SARS-CoV-2 variants can potentially break set epidemiological barriers in COVID-19. <i>Journal of Medical Virology</i> , 2022, 94, 1300-1314.	2.5	32
324	CRISPR-Cas12a-Based Detection for the Major SARS-CoV-2 Variants of Concern. <i>Microbiology Spectrum</i> , 2021, 9, e0101721.	1.2	40
325	A Novel Strategy for the Detection of SARS-CoV-2 Variants Based on Multiplex PCR-Mass Spectrometry Minisequencing Technology. <i>Microbiology Spectrum</i> , 2021, 9, e0126721.	1.2	19
326	The Impact of Social Media on the Acceptance of the COVID-19 Vaccine: A Cross-Sectional Study from Saudi Arabia. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 2673-2681.	0.8	21
327	Molecular docking and pharmacokinetic studies of phytochemicals from Nigerian Medicinal Plants as promising inhibitory agents against SARS-CoV-2 methyltransferase (nsp16). <i>Journal of Genetic Engineering and Biotechnology</i> , 2021, 19, 172.	1.5	7
328	Temperature and oxygen saturation in skilled nursing facility residents positive for SARS-CoV-2 prior to symptom onset. <i>Journal of the American Geriatrics Society</i> , 2022, 70, 363-369.	1.3	1
329	SARS-CoV-2 variants of concern dominate in Lahore, Pakistan in April 2021. <i>Microbial Genomics</i> , 2021, 7, .	1.0	9
330	Evolutionary and Phenotypic Characterization of Two Spike Mutations in European Lineage 20E of SARS-CoV-2. <i>MBio</i> , 2021, 12, e0231521.	1.8	6
331	Real-Time Projections of SARS-CoV-2 B.1.1.7 Variant in a University Setting, Texas, USA. <i>Emerging Infectious Diseases</i> , 2021, 27, 3188-3190.	2.0	3
332	Rapid test to assess the escape of SARS-CoV-2 variants of concern. <i>Science Advances</i> , 2021, 7, eabl7682.	4.7	21
333	A k-mer Based Approach for SARS-CoV-2 Variant Identification. <i>Lecture Notes in Computer Science</i> , 2021, , 153-164.	1.0	32
334	An overview of the ongoing challenges in SARS-CoV-2 global control. <i>German Journal of Microbiology</i> , 2021, 1, 1-18.	0.3	17
335	Inferring the stabilization effects of SARS-CoV-2 variants on the binding with ACE2 receptor. <i>Communications Biology</i> , 2022, 5, 1421.	2.0	19
337	Point-of-Care Platform for Rapid Multiplexed Detection of SARS-CoV-2 Variants and Respiratory Pathogens. <i>Advanced Materials Technologies</i> , 2022, 7, 2101013.	3.0	18
338	Yeast surface display-based identification of ACE2 mutations that modulate SARS-CoV-2 spike binding across multiple mammalian species. <i>Protein Engineering, Design and Selection</i> , 2022, 35, .	1.0	1
339	COVID-19 to go? The role of disasters and evacuation in the COVID-19 pandemic. <i>Global Environmental Change</i> , 2022, 73, 102471.	3.6	11
340	Computational modelling of potentially emerging SARS-CoV-2 spike protein RBDs mutations with higher binding affinity towards ACE2: A structural modelling study. <i>Computers in Biology and Medicine</i> , 2022, 141, 105163.	3.9	17

#	ARTICLE	IF	CITATIONS
341	Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: Findings from a large observational study in Israel. <i>Preventive Medicine</i> , 2022, 155, 106947.	1.6	27
342	Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112527.	2.5	34
343	Striking lineage diversity of severe acute respiratory syndrome coronavirus 2 from non-human sources. <i>One Health</i> , 2022, 14, 100363.	1.5	3
344	Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections. <i>Nature Communications</i> , 2022, 13, 532.	5.8	53
345	Absolute quantitation of individual SARS-CoV-2 RNA molecules provides a new paradigm for infection dynamics and variant differences. <i>ELife</i> , 2022, 11, .	2.8	33
346	Antiviral Effects of Artemisinin and Its Derivatives against SARS-CoV-2 Main Protease: Computational Evidences and Interactions with ACE2 Allelic Variants. <i>Pharmaceuticals</i> , 2022, 15, 129.	1.7	23
347	Three waves changes, new variant strains, and vaccination effect against COVID-19 pandemic. <i>International Journal of Biological Macromolecules</i> , 2022, 204, 161-168.	3.6	147
348	Designing of a bispecific antibody against SARS-CoV-2 spike glycoprotein targeting human entry receptors DPP4 and ACE2. <i>Human Immunology</i> , 2022, 83, 346-355.	1.2	7
349	Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model. <i>Vaccine</i> , 2022, 40, 1289-1298.	1.7	9
350	Rapid detection of the widely circulating B.1.617.2 (Delta) SARS-CoV-2 variant. <i>Pathology</i> , 2022, 54, 351-356.	0.3	13
351	The ins and outs of SARS-CoV-2 variants of concern (VOCs). <i>Archives of Virology</i> , 2022, 167, 327-344.	0.9	35
353	Developing an Amplification Refractory Mutation System-Quantitative Reverse Transcription-PCR Assay for Rapid and Sensitive Screening of SARS-CoV-2 Variants of Concern. <i>Microbiology Spectrum</i> , 2022, 10, e0143821.	1.2	11
354	Setting-Up a Rapid SARS-CoV-2 Genome Assessment by Next-Generation Sequencing in an Academic Hospital Center (LPCE, Louis Pasteur Hospital, Nice, France). <i>Frontiers in Medicine</i> , 2021, 8, 730577.	1.2	5
356	Evaluating Antibody Mediated Protection against Alpha, Beta, and Delta SARS-CoV-2 Variants of Concern in K18-hACE2 Transgenic Mice. <i>Journal of Virology</i> , 2022, 96, jvi0218421.	1.5	14
357	Outcomes of hospital-acquired SARS-CoV-2 infection in the Canadian first wave epicentre: a retrospective cohort study. <i>CMAJ Open</i> , 2022, 10, E74-E81.	1.1	4
358	New Coronavirus Variants are Creating More Challenges to Global Healthcare System: A Brief Report on the Current Knowledge. <i>BMC Clinical Pathology</i> , 2022, 15, 2632010X2210755.	0.7	85
359	Rapid Detection and Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Variant in a Returning Traveler. <i>Clinical Infectious Diseases</i> , 2022, 75, e350-e353.	2.9	7
361	A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2. <i>Cell Reports</i> , 2022, 38, 110256.	2.9	19

#	ARTICLE	IF	CITATIONS
362	Epidemiological analysis of the emergence and disappearance of the SARS-CoV-2 Kappa variant within a region of British Columbia, Canada. <i>Canada Communicable Disease Report</i> , 2022, 48, 22-26.	0.6	0
363	Testing the predictive accuracy of COVID-19 forecasts. <i>International Journal of Forecasting</i> , 2023, 39, 606-622.	3.9	6
364	A new infodemiological approach through Google Trends: longitudinal analysis of COVID-19 scientific and infodemic names in Italy. <i>BMC Medical Research Methodology</i> , 2022, 22, 33.	1.4	17
365	SARS-CoV-2 Transmission and Prevention in the Era of the Delta Variant. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 267-293.	1.9	10
366	SARS-CoV-2 multiplex RT-PCR to detect variants of concern (VOCs) in Malaysia, between January to May 2021. <i>Journal of Virological Methods</i> , 2022, 301, 114462.	1.0	25
367	Genomic characterization of SARS-CoV-2 and its association with clinical outcomes: a 1-year longitudinal study of the pandemic in Colombia. <i>International Journal of Infectious Diseases</i> , 2022, 116, 91-100.	1.5	5
368	Prevalence and factors associated with COVID-19 vaccine acceptance in Zambia: a web-based cross-sectional study. <i>Pan African Medical Journal</i> , 2022, 41, 112.	0.3	13
369	Multiple expansions of globally uncommon SARS-CoV-2 lineages in Nigeria. <i>Nature Communications</i> , 2022, 13, 688.	5.8	23
370	Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) Variants in United States, June 2021–January 2022. <i>Morbidity and Mortality Weekly Report</i> , 2022, 71, 206-211.	9.0	128
371	The Complexity of SARS-CoV-2 Infection and the COVID-19 Pandemic. <i>Frontiers in Microbiology</i> , 2022, 13, 789882.	1.5	20
372	Prevalence and circulation patterns of SARS-CoV-2 variants in European sewage mirror clinical data of 54 European cities. <i>Water Research</i> , 2022, 214, 118162.	5.3	45
373	Characterizing the effective reproduction number during the COVID-19 pandemic: Insights from Qatar's experience. <i>Journal of Global Health</i> , 2022, 12, 05004.	1.2	7
374	Co-circulation of SARS-CoV-2 Alpha and Gamma variants in Italy, February and March 2021. <i>Eurosurveillance</i> , 2022, 27, .	3.9	20
375	Epidemiology and genetic diversity of SARS-CoV-2 lineages circulating in Africa. <i>IScience</i> , 2022, 25, 103880.	1.9	6
376	Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications. <i>Current Microbiology</i> , 2022, 79, 20.	1.0	48
377	Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta. <i>Nature</i> , 2022, 602, 307-313.	13.7	79
378	A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	43
379	The race for a COVID-19 vaccine: where are we up to?. <i>Expert Review of Vaccines</i> , 2022, 21, 355-376.	2.0	11

#	ARTICLE	IF	CITATIONS
380	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)â€™Specific Memory B Cells From Individuals With Diverse Disease Severities Recognize SARS-CoV-2 Variants of Concern. <i>Journal of Infectious Diseases</i> , 2022, 225, 947-956.	1.9	13
381	Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003879.	3.9	54
382	SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 777212.	1.8	29
383	Omicron SARS-CoV-2 Variant Spike Protein Shows an Increased Affinity to the Human ACE2 Receptor: An In Silico Analysis. <i>Pathogens</i> , 2022, 11, 45.	1.2	44
384	B.1.617.2 (Delta) Variant of SARS-CoV-2: features, transmission and potential strategies. <i>International Journal of Biological Sciences</i> , 2022, 18, 1844-1851.	2.6	34
385	Inhibitor screening using microarray identifies the high capacity of neutralizing antibodies to Spike variants in SARS-CoV-2 infection and vaccination. <i>Theranostics</i> , 2022, 12, 2519-2534.	4.6	3
386	Origin of the tight binding mode to ACE2 triggered by multi-point mutations in the omicron variant: a dynamic insight. <i>Physical Chemistry Chemical Physics</i> , 2022, 24, 8724-8737.	1.3	11
387	Cultural-Religious Approach: An Effective Community-Based Disaster Management Strategy for Reducing the Mortality and Morbidity of the Fourth Wave of Coronavirus Pandemic Caused by the Lineage B.1.1.7 (the British Variant) in Iran (Spring 2021). <i>The Malaysian Journal of Medical Sciences</i> , 2022, 29, 154-156.	0.3	0
388	Study of Different Deep Learning Methods for Coronavirus (COVID-19) Pandemic: Taxonomy, Survey and Insights. <i>Sensors</i> , 2022, 22, 1890.	2.1	14
389	An approach to compare performance of surgical masks for fighting against the COVID-19 pandemic. <i>Aerosol Science and Technology</i> , 2022, 56, 434-445.	1.5	1
390	Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses. <i>Science Advances</i> , 2022, 8, .	4.7	77
391	Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy. <i>Medical Microbiology and Immunology</i> , 2022, 211, 79-103.	2.6	9
392	Computational Investigations for Identification of Bioactive Molecules from <i>Baccaurea ramiflora</i> and <i>Bergenia ciliata</i> as Inhibitors of SARS-CoV-2 M ^{pro} . <i>Polycyclic Aromatic Compounds</i> , 2023, 43, 2459-2487.	1.4	25
393	SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study. <i>Lancet Microbe</i> , The, 2022, 3, e348-e356.	3.4	107
394	SARS-CoV-2 and Influenza A Virus Coinfections in Ferrets. <i>Journal of Virology</i> , 2022, 96, JVI0179121.	1.5	23
395	E-Volve: understanding the impact of mutations in SARS-CoV-2 variants spike protein on antibodies and ACE2 affinity through patterns of chemical interactions at protein interfaces. <i>PeerJ</i> , 2022, 10, e13099.	0.9	3
396	New laboratory evidence for the association between endothelial dysfunction and COVIDâ€™19 disease progression. <i>Journal of Medical Virology</i> , 2022, 94, 3112-3120.	2.5	12
397	Basic virology of SARS-CoV 2. <i>Indian Journal of Medical Microbiology</i> , 2022, 40, 182-186.	0.3	12

#	ARTICLE	IF	CITATIONS
398	High Seroprevalence of SARS-CoV-2 in White-Tailed Deer (<i>Odocoileus virginianus</i>) at One of Three Captive Cervid Facilities in Texas. <i>Microbiology Spectrum</i> , 2022, 10, e0057622.	1.2	30
399	Evolving Risk of Acute Kidney Injury in COVID-19 Hospitalized Patients: A Single Center Retrospective Study. <i>Medicina (Lithuania)</i> , 2022, 58, 443.	0.8	4
400	Mutations in the genome of severe acute respiratory syndrome coronavirus 2: implications for COVID-19 severity and progression. <i>Journal of International Medical Research</i> , 2022, 50, 030006052210864.	0.4	5
401	The association of intensity and duration of non-pharmacological interventions and implementation of vaccination with COVID-19 infection, death, and excess mortality: natural experiment in 22 European countries. <i>Journal of Infection and Public Health</i> , 2022, 15, 499-507.	1.9	13
402	SARS-CoV-2: vaccinology and emerging therapeutics; challenges and future developments. <i>Therapeutic Delivery</i> , 2022, 13, 187-203.	1.2	8
403	Using Spike Gene Target Failure to Estimate Growth Rate of the Alpha and Omicron Variants of SARS-CoV-2. <i>Journal of Clinical Microbiology</i> , 2022, 60, e0257321.	1.8	3
404	Global landscape of SARS-CoV-2 genomic surveillance and data sharing. <i>Nature Genetics</i> , 2022, 54, 499-507.	9.4	138
405	Acute Neurological Manifestations of COVID-19 Patients From Three Tertiary Care Hospitals in Qatar. <i>Cureus</i> , 2022, 14, e23150.	0.2	0
406	An issue of concern: unique truncated ORF8 protein variants of SARS-CoV-2. <i>PeerJ</i> , 2022, 10, e13136.	0.9	7
407	Spike protein of SARS-CoV-2 variants: a brief review and practical implications. <i>Brazilian Journal of Microbiology</i> , 2022, 53, 1133-1157.	0.8	22
408	Emergence, evolution, and vaccine production approaches of SARS-CoV-2 virus: Benefits of getting vaccinated and common questions. <i>Saudi Journal of Biological Sciences</i> , 2022, 29, 1981-1997.	1.8	5
409	Progress on SARS-CoV-2 3CLpro Inhibitors: Inspiration from SARS-CoV 3CLpro Peptidomimetics and Small-Molecule Anti-Inflammatory Compounds. <i>Drug Design, Development and Therapy</i> , 2022, Volume 16, 1067-1082.	2.0	23
410	Simultaneous Measurement of IgM and IgG Antibodies to SARS-CoV-2 Spike, RBD, and Nucleocapsid Multiplexed in a Single Assay on the xMAP INTELLIFLEX DR-SE Flow Analyzer. <i>Microbiology Spectrum</i> , 2022, , e0250721.	1.2	6
411	MA-Net:Mutex attention network for COVID-19 diagnosis on CT images. <i>Applied Intelligence</i> , 2022, , 1-16.	3.3	1
412	Simple Formulae, Deep Learning and Elaborate Modelling for the COVID-19 Pandemic. <i>Encyclopedia</i> , 2022, 2, 679-689.	2.4	1
413	Application of pseudovirus system in the development of vaccine, antiviral-drugs, and neutralizing antibodies. <i>Microbiological Research</i> , 2022, 258, 126993.	2.5	22
414	The non-pharmaceutical interventions may affect the advantage in transmission of mutated variants during epidemics: A conceptual model for COVID-19. <i>Journal of Theoretical Biology</i> , 2022, 542, 111105.	0.8	5
415	SARS-CoV-2 infections in mRNA vaccinated individuals are biased for viruses encoding spike E484K and associated with reduced infectious virus loads that correlate with respiratory antiviral IgG levels. <i>Journal of Clinical Virology</i> , 2022, 150-151, 105151.	1.6	11

#	ARTICLE	IF	CITATIONS
416	The Influence of SARS-CoV-2 Variants on National Case-Fatality Rates: Correlation and Validation Study. <i>Jmirx Med</i> , 2022, 3, e32935.	0.2	9
417	Spike2Vec: An Efficient and Scalable Embedding Approach for COVID-19 Spike Sequences. , 2021, , .		38
420	Genomic Epidemiology of SARS-CoV-2 Divulge B.1, B.1.36, and B.1.1.7 as the Most Dominant Lineages in First, Second, and Third Wave of SARS-CoV-2 Infections in Pakistan. <i>Microorganisms</i> , 2021, 9, 2609.	1.6	17
421	Analysis of Clinical Characteristics and Virus Strains Variation of Patients Infected With SARS-CoV-2 in Jiangsu Provinceâ€”A Retrospective Study. <i>Frontiers in Public Health</i> , 2021, 9, 791600.	1.3	7
422	Robust clinical detection of SARSâ€”CoVâ€”2 variants by RTâ€”PCR/MALDIâ€”TOF multitarget approach. <i>Journal of Medical Virology</i> , 2022, 94, 1606-1616.	2.5	9
423	Persistence of Robust Humoral Immune Response in Coronavirus Disease 2019 Convalescent Individuals Over 12 Months After Infection. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab626.	0.4	6
424	An Overview of COVID-19 and Its Vaccines. <i>Biology Bulletin Reviews</i> , 2021, 11, 47-64.	0.3	0
426	Advances in the design and development of SARS-CoV-2 vaccines. <i>Military Medical Research</i> , 2021, 8, 67.	1.9	26
427	Iota-Carrageenan Inhibits Replication of SARS-CoV-2 and the Respective Variants of Concern Alpha, Beta, Gamma and Delta. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13202.	1.8	20
428	The co-circulating transmission dynamics of SARS-CoV-2 Alpha and Eta variants in Nigeria: A retrospective modeling study of COVID-19. <i>Journal of Global Health</i> , 2021, 11, 05028.	1.2	4
429	Evolution of enhanced innate immune evasion by SARS-CoV-2. <i>Nature</i> , 2022, 602, 487-495.	13.7	237
430	Targeting conserved N-glycosylation blocks SARS-CoV-2 variant infection in vitro. <i>EBioMedicine</i> , 2021, 74, 103712.	2.7	37
431	Vaccination and Covid 19 Infections. <i>Medicina Interna (Bucharest, Romania: 1991)</i> , 2022, 19, 97-105.	0.1	0
432	Comparative genomics, evolutionary epidemiology, and RBD-hACE2 receptor binding pattern in B.1.1.7 (Alpha) and B.1.617.2 (Delta) related to their pandemic response in UK and India. <i>Infection, Genetics and Evolution</i> , 2022, 101, 105282.	1.0	7
435	SARS-CoV-2 N-gene mutation leading to Xpert Xpress SARS-CoV-2 assay instability. <i>Pathology</i> , 2022, , .	0.3	8
436	Household Transmission and Symptomology of Severe Acute Respiratory Syndrome Coronavirus 2 Alpha Variant among Childrenâ€”California and Colorado, 2021. <i>Journal of Pediatrics</i> , 2022, 247, 29-37.e7.	0.9	5
437	Clinical Characteristics, Transmissibility, Pathogenicity, Susceptible Populations, and Re-infectivity of Prominent COVID-19 Variants. , 2022, 13, 402.		28
438	Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. <i>BioDrugs</i> , 2022, 36, 231-323.	2.2	24

#	ARTICLE	IF	CITATIONS
440	Coronavirus Infection and Cholesterol Metabolism. <i>Frontiers in Immunology</i> , 2022, 13, 791267.	2.2	31
441	Resilience of Spike-Specific Immunity Induced by COVID-19 Vaccines against SARS-CoV-2 Variants. <i>Biomedicines</i> , 2022, 10, 996.	1.4	3
442	Combining genomic and epidemiological data to compare the transmissibility of SARS-CoV-2 variants Alpha and Iota. <i>Communications Biology</i> , 2022, 5, 439.	2.0	9
443	Precision health diagnostic and surveillance network uses <i>S</i> gene target failure (SGTF) combined with sequencing technologies to track emerging SARS-CoV-2 variants. <i>Immunity, Inflammation and Disease</i> , 2022, 10, .	1.3	4
445	Recent trends in next generation immunoinformatics harnessed for universal coronavirus vaccine design. <i>Pathogens and Global Health</i> , 2023, 117, 134-151.	1.0	2
446	Immune recall improves antibody durability and breadth to SARS-CoV-2 variants. <i>Science Immunology</i> , 2022, 7, eabp8328.	5.6	40
447	Mental health in COVID-19 Delta variant survivors and healthcare workers during 2021 outbreak in Nanjing, China: a cross-sectional study. <i>Canadian Journal of Physiology and Pharmacology</i> , 2022, , .	0.7	0
448	Recent Chronology of COVID-19 Pandemic. <i>Frontiers in Public Health</i> , 2022, 10, .	1.3	21
449	Physicochemical effect of the N501Y, E484K/Q, K417N/T, L452R and T478K mutations on the SARS-CoV-2 spike protein RBD and its influence on agent fitness and on attributes developed by emerging variants of concern. <i>Virology</i> , 2022, 572, 44-54.	1.1	21
450	COVID-19 Vaccination and Public Health Countermeasures on Variants of Concern in Canada: Evidence From a Spatial Hierarchical Cluster Analysis. <i>JMIR Public Health and Surveillance</i> , 2022, 8, e31968.	1.2	5
451	Screening and Whole Genome Sequencing of SARS-CoV-2 Circulating During the First Three Waves of the COVID-19 Pandemic in Libreville and the Haut-Ogooué Province in Gabon. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	7
452	Comparative phylodynamics reveals the evolutionary history of SARS-CoV-2 emerging variants in the Arabian Peninsula. <i>Virus Evolution</i> , 2022, 8, .	2.2	3
453	Analysis of 256 pediatric oral and maxillofacial emergency inpatients during the outbreak of COVID-19. <i>Dental Traumatology</i> , 2022, 38, 367-373.	0.8	5
454	Role of COVID-19 Vaccines in SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	37
455	COVID-19 Outcomes and Vaccination in Patients with Spondyloarthritis. <i>Rheumatology and Therapy</i> , 0, .	1.1	1
456	Characterizing the Severity of SARS-CoV-2 Variants at a Single Pediatric Center. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	2
457	SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies. <i>International Reviews of Immunology</i> , 2023, 42, 393-414.	1.5	26
458	Emergency SARS-CoV-2 variants of concern: rapidly direct RT-qPCR detection without RNA extraction, clinical comparison, cost-effective, and high-throughput. <i>Aging</i> , 0, , .	1.4	1

#	ARTICLE	IF	CITATIONS
460	SARS-CoV-2 vaccine challenge based on spike glycoprotein against several new variants. <i>Clinical and Experimental Vaccine Research</i> , 2022, 11, 173.	1.1	0
461	CAVES: A Novel Tool for Comparative Analysis of Variant Epitope Sequences. <i>Viruses</i> , 2022, 14, 1152.	1.5	0
462	Household Secondary Transmission of the Severe Acute Respiratory Syndrome Coronavirus 2 Alpha Variant From a Community Cluster in a Nursery in Japan. <i>Pediatric Infectious Disease Journal</i> , 0, Publish Ahead of Print, .	1.1	1
463	Comparison of infection-induced and vaccine-induced immunity against COVID-19 in patients with cirrhosis. <i>Hepatology</i> , 2023, 77, 186-196.	3.6	11
464	Depending on Epitope Profile of COVID-19 mRNA Vaccine Recipients: Are They More Efficient Against the Arising Viral Variants? An Opinion Article. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	0
465	Synergistic Antiviral Activity of Pamapimod and Pioglitazone against SARS-CoV-2 and Its Variants of Concern. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6830.	1.8	5
466	Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	59
467	Comparison of clinical characteristics and outcomes of hospitalized patients with seasonal coronavirus infection and COVID-19: a retrospective cohort study. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	1
469	SARS-CoV-2 Delta spike protein enhances the viral fusogenicity and inflammatory cytokine production. <i>IScience</i> , 2022, 25, 104759.	1.9	11
470	Long COVID and symptom trajectory in a representative sample of Americans in the first year of the pandemic. <i>Scientific Reports</i> , 2022, 12, .	1.6	31
471	Covid-19 in America: Global supply chain reconsidered. <i>World Economy</i> , 2023, 46, 256-275.	1.4	5
472	Interferon resistance of emerging SARS-CoV-2 variants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	63
473	Net-Shaped DNA Nanostructures Designed for Rapid/Sensitive Detection and Potential Inhibition of the SARS-CoV-2 Virus. <i>Journal of the American Chemical Society</i> , 2023, 145, 20214-20228.	6.6	33
475	Molecular adaptations during viral epidemics. <i>EMBO Reports</i> , 2022, 23, .	2.0	18
476	Dynamics of Viral Infection and Evolution of SARS-CoV-2 Variants in the Calabria Area of Southern Italy. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	10
477	Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines. <i>Nature Communications</i> , 2022, 13, .	5.8	28
479	Outbreak of Middle East Respiratory Syndrome Coronavirus in Camels and Probable Spillover Infection to Humans in Kenya. <i>Viruses</i> , 2022, 14, 1743.	1.5	8
480	Non-pharmaceutical interventions and covid-19 burden in the United States: retrospective, observational cohort study. , 2022, 1, e000030.		7

#	ARTICLE	IF	CITATIONS
481	Identifying Drug-Induced Liver Injury Associated With Inflammation-Drug and Drug-Drug Interactions in Pharmacologic Treatments for COVID-19 by Bioinformatics and System Biology Analyses: The Role of Pregnane X Receptor. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
482	Containing novel SARS-CoV-2 variants at source is possible with high-intensity sequencing. , 2022, 1, .		3
484	Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines. <i>Journal of Medical Virology</i> , 2022, 94, 5678-5690.	2.5	16
485	Second round of an interlaboratory comparison of SARS-CoV2 molecular detection assays used by 45 veterinary diagnostic laboratories in the United States. <i>Journal of Veterinary Diagnostic Investigation</i> , 2022, 34, 825-834.	0.5	3
486	Host genetic diversity and genetic variations of SARS-CoV-2 in COVID-19 pathogenesis and the effectiveness of vaccination. <i>International Immunopharmacology</i> , 2022, 111, 109128.	1.7	9
487	SARS-CoV-2 infection in pediatric population before and during the Delta (B.1.617.2) and Omicron (B.1.1.529) variants era. <i>Virology Journal</i> , 2022, 19, .	1.4	41
488	The mechanisms of immune response and evasion by the main SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 105044.	1.9	8
489	Wastewater to clinical case (WC) ratio of COVID-19 identifies insufficient clinical testing, onset of new variants of concern and population immunity in urban communities. <i>Science of the Total Environment</i> , 2022, 853, 158547.	3.9	19
490	Emergence of COVID-19 Variants and Its Global Impact. , 2022, , 183-201.		1
491	Efficient Approximate Kernel Based Spike Sequence Classification. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2023, 20, 3376-3388.	1.9	11
492	Diagnostic Accuracy of Four Serological Tests for COVID-19 and Differences in Antibody Positivity Rates Based on the Need for Treatment or Ventilator Support. <i>Journal of St Marianna University</i> , 2022, 13, 29-37.	0.1	0
493	Antibody-mediated immunity to SARS-CoV-2 spike. <i>Advances in Immunology</i> , 2022, , 1-69.	1.1	12
494	Prognosis of COVID-19 in the middle eastern population, knowns and unknowns. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	1
495	SARS-CoV-2 Delta variant induces enhanced pathology and inflammatory responses in K18-hACE2 mice. <i>PLoS ONE</i> , 2022, 17, e0273430.	1.1	17
497	Comparison of clinical characteristics among patients infected with alpha vs. delta SARS-CoV-2 variants. <i>Wiener Klinische Wochenschrift</i> , 0, , .	1.0	0
498	The neutralization of B.1.617.1 and B.1.1.529 sera from convalescent patients and BBIBP-CorV vaccines. <i>IScience</i> , 2022, 25, 105016.	1.9	2
500	An in silico pipeline approach uncovers a potentially intricate network involving spike SARS-CoV-2 RNA, RNA vaccines, host RNA-binding proteins (RBPs), and host miRNAs at the cellular level. <i>Journal of Genetic Engineering and Biotechnology</i> , 2022, 20, 129.	1.5	1
501	Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosis. <i>Journal of Hepatology</i> , 2022, 77, 1349-1358.	1.8	23

#	ARTICLE	IF	CITATIONS
502	Agile design and development of a high throughput cobas SARS-CoV-2 RT-PCR diagnostic test. Heliyon, 2022, 8, e10591.	1.4	0
503	Validation of reduced S-gene target performance and failure for rapid surveillance of SARS-CoV-2 variants. PLoS ONE, 2022, 17, e0275150.	1.1	11
504	Clustering SARS-CoV-2 Variants from Raw High-Throughput Sequencing Reads Data. Lecture Notes in Computer Science, 2022, , 133-148.	1.0	8
505	Comparison of Clinical Characteristics and Outcomes of Hospitalized Patients Infected with the D614G Strain or Alpha Variant of COVID-19 in Taiwan: A Multi-Center Cohort Study. International Journal of Medical Sciences, 2022, 19, 1912-1919.	1.1	1
506	Importancia de la vigilancia genómica de SARS-CoV-2 en los tiempos de las vacunas contra la COVID-19. Revista De La Universidad Industrial De Santander Salud, 2022, 54, .	0.0	0
507	Insight into genomic organization of pathogenic coronaviruses, SARS-CoV-2: Implication for emergence of new variants, laboratory diagnosis and treatment options. Frontiers in Molecular Medicine, 0, 2, .	0.6	0
508	Arylcoumarin perturbs SARS-CoV-2 pathogenesis by targeting the S-protein/ACE2 interaction. Scientific Reports, 2022, 12, .	1.6	0
509	Neutralization of five SARS-CoV-2 variants of concern by convalescent and BBIBP-CorV vaccinee serum. Virologica Sinica, 2022, 37, 831-841.	1.2	2
510	Pulling it all together: where do we go from here?. , 2023, , 417-454.		0
511	Long-term kidney function recovery and mortality after COVID-19-associated acute kidney injury: an international multi-centre observational cohort study. EClinicalMedicine, 2023, 55, 101724.	3.2	26
512	Prolonged Use of Surgical Masks and Respirators Affects the Protection and Comfort for Healthcare Workers. Materials, 2022, 15, 7918.	1.3	7
514	Mitigation of COVID-19 at the 2021 National Collegiate Athletic Association Men's Basketball Tournament. BMC Public Health, 2022, 22, .	1.2	0
515	Structural basis for the broad and potent cross-reactivity of an N501Y-centric antibody against sarbecoviruses. Frontiers in Immunology, 0, 13, .	2.2	0
516	Structural analysis of a simplified model reproducing SARS-CoV-2 S RBD/ACE2 binding site. Heliyon, 2022, 8, e11568.	1.4	4
517	Characterization and analysis of linear epitopes corresponding to SARS-CoV-2 outbreak in Jilin Province, China. Journal of Medical Virology, 2023, 95, .	2.5	4
518	The application of a novel 5-in-1 multiplex reverse transcriptase-polymerase chain reaction assay for rapid detection of SARS-CoV-2 and differentiation between variants of concern. International Journal of Infectious Diseases, 2023, 127, 56-62.	1.5	1
519	COVIDSeq as Laboratory Developed Test (LDT) for Diagnosis of SARS-CoV-2 Variants of Concern (VOC). Archives of Clinical and Biomedical Research, 2022, 06, .	0.1	6
520	A SARS-CoV-2 neutralizing antibody discovery by single cell sequencing and molecular modeling. Journal of Biomedical Research, 2023, 37, 166.	0.7	1

#	ARTICLE	IF	CITATIONS
521	Clinical and laboratory features of COVID-19 patients infected with SARS-CoV-2 variant B.1.1.7 versus those infected with other SARS-CoV-2 strains: A retrospective observational study. <i>Journal of Acute Disease</i> , 2022, 11, 236.	0.0	0
522	Wastewater-Based Epidemiology Mitigates COVID-19 Outbreaks at a Food Processing Facility near the Mexico-U.S. Border—November 2020—March 2022. <i>Viruses</i> , 2022, 14, 2684.	1.5	2
523	As the SARS-CoV-2 virus evolves, should Omicron subvariant BA.2 be subjected to quarantine, or should we learn to live with it?. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	5
524	Challenges and developments in universal vaccine design against SARS-CoV-2 variants. <i>Npj Vaccines</i> , 2022, 7, .	2.9	25
525	A 2-Gene Host Signature for Improved Accuracy of COVID-19 Diagnosis Agnostic to Viral Variants. <i>MSystems</i> , 2023, 8, .	1.7	2
526	Retrospective Analysis of Wastewater-Based Epidemiology of SARS-CoV-2 in Residences on a Large College Campus: Relationships between Wastewater Outcomes and COVID-19 Cases across Two Semesters with Different COVID-19 Mitigation Policies. <i>ACS ES&T Water</i> , 2023, 3, 16-29.	2.3	3
527	Real-Time Polymerase Chain Reaction: Current Techniques, Applications, and Role in COVID-19 Diagnosis. <i>Genes</i> , 2022, 13, 2387.	1.0	20
528	Epidemiology and Characteristics of SARS-CoV-2 Variants of Concern: The Impacts of the Spike Mutations. <i>Microorganisms</i> , 2023, 11, 30.	1.6	11
529	Protein post-translational modification in SARS-CoV-2 and host interaction. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
530	In-depth genetic characterization of the SARS-CoV-2 pandemic in a two-year frame in North Macedonia using second and third generation sequencing technologies. <i>Frontiers in Virology</i> , 0, 2, .	0.7	0
531	European Black Elderberry Fruit Extract Inhibits Replication of SARS-CoV-2 In Vitro. <i>Nutraceuticals</i> , 2023, 3, 91-106.	0.6	3
532	Humoral Immune Response Profile of COVID-19 Reveals Severity and Variant-Specific Epitopes: Lessons from SARS-CoV-2 Peptide Microarray. <i>Viruses</i> , 2023, 15, 248.	1.5	4
533	A perspective on SARS-CoV-2 virus-like particles vaccines. <i>International Immunopharmacology</i> , 2023, 115, 109650.	1.7	6
534	On the Evolutionary Trajectory of SARS-CoV-2: Host Immunity as a Driver of Adaptation in RNA Viruses. <i>Viruses</i> , 2023, 15, 70.	1.5	2
536	Unglycosylated Soluble SARS-CoV-2 Receptor Binding Domain (RBD) Produced in E. coli Combined with the Army Liposomal Formulation Containing QS21 (ALFQ) Elicits Neutralizing Antibodies against Mismatched Variants. <i>Vaccines</i> , 2023, 11, 42.	2.1	5
537	Assessment of the Prevalence and Incidence of COVID-19 in Saudi Arabia. <i>Journal of Multidisciplinary Healthcare</i> , 0, Volume 16, 227-236.	1.1	0
538	Cost-Effectiveness Analysis of COVID-19 Vaccine Booster Dose in the Thai Setting during the Period of Omicron Variant Predominance. <i>Tropical Medicine and Infectious Disease</i> , 2023, 8, 91.	0.9	4
539	Targeting Viral ORF3a Protein: A New Approach to Mitigate COVID-19 Induced Immune Cell Apoptosis and Associated Respiratory Complications. <i>Advanced Pharmaceutical Bulletin</i> , 2023, 13, 678-687.	0.6	1

#	ARTICLE	IF	CITATIONS
540	Generating simple classification rules to predict local surges in COVID-19 hospitalizations. <i>Health Care Management Science</i> , 0, , .	1.5	1
542	Emergence and spread of two SARS-CoV-2 variants of interest in Nigeria. <i>Nature Communications</i> , 2023, 14, .	5.8	8
543	Global SARS-CoV-2 genomic surveillance: What we have learned (so far). <i>Infection, Genetics and Evolution</i> , 2023, 108, 105405.	1.0	21
544	Spike-mediated viral membrane fusion is inhibited by a specific anti-IFITM2 monoclonal antibody. <i>Antiviral Research</i> , 2023, 211, 105546.	1.9	2
545	Clinical Value of Platelets and Coagulation Parameters in Predicting the Severity of Delta Variant SARS-CoV-2. <i>Pathobiology</i> , 0, , 1-10.	1.9	1
546	SARS-CoV-2 vaccine alleviates disease burden and severity in liver transplant recipients even with low antibody titers. <i>Hepatology Communications</i> , 2023, 7, e0025-e0025.	2.0	0
547	Reads2Vec: Efficient Embedding of Raw High-Throughput Sequencing Reads Data. <i>Journal of Computational Biology</i> , 2023, 30, 469-491.	0.8	8
549	Optimized workplace risk mitigation measures for SARS-CoV-2 in 2022. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
550	An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. <i>Heliyon</i> , 2023, 9, e13952.	1.4	28
552	Teaching Medical Microbiology With a Web-Based Course During the COVID-19 Pandemic: Retrospective Before-and-After Study. <i>JMIR Medical Education</i> , 0, 9, e39680.	1.2	1
553	COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study. <i>Cancers</i> , 2023, 15, 1497.	1.7	3
554	Novelty Search Promotes Antigenic Diversity in Microbial Pathogens. <i>Pathogens</i> , 2023, 12, 388.	1.2	0
555	Different Variants of SARS-CoV-2: A Comprehensive Review on Mutation Patterns and Pathogenicity. <i>Coronaviruses</i> , 2023, 4, .	0.2	1
556	Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies. <i>Viruses</i> , 2023, 15, 944.	1.5	19
557	Phytochemicals of <i>Withania somnifera</i> as a Future Promising Drug against SARS-CoV-2: Pharmacological Role, Molecular Mechanism, Molecular Docking Evaluation, and Efficient Delivery. <i>Microorganisms</i> , 2023, 11, 1000.	1.6	2
558	COVID-19 and immunity. , 2023, , 3-32.		0
583	Exploring Textural Behavior of Novel Coronavirus (SARS-CoV-2) Through UV Microscope Images. <i>Lecture Notes in Electrical Engineering</i> , 2023, , 355-369.	0.3	1
586	Traditional Herbal Medicines and Their Active Constituents in Combating SARS-CoV-2 Infection. , 2023, , 137-188.		0

#	ARTICLE	IF	CITATIONS
594	Coronavirus disease (COVID-19) pandemic public health challenges in Iraq: Current status and future implications. AIP Conference Proceedings, 2023, , .	0.3	0
595	Genomic analysis of microbial infections. , 2024, , 1907-1929.		0
601	Overview of diagnostic tools and nano-based therapy of SARS-CoV-2 infection. Chemical Papers, 2024, 78, 2123-2154.	1.0	0
605	Therapeutic landscape of SARS-CoV-2. , 2024, , 83-99.		0